| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥109.14B | ¥110.48B | -1.2% |
| Cost of Sales | ¥68.18B | ¥67.97B | +0.3% |
| Gross Profit | ¥40.96B | ¥42.51B | -3.7% |
| SG&A Expenses | ¥20.31B | ¥19.19B | +5.8% |
| Operating Income | ¥20.65B | ¥23.32B | -11.5% |
| Non-operating Income | ¥1.32B | ¥1.22B | +8.3% |
| Non-operating Expenses | ¥340M | ¥951M | -64.2% |
| Ordinary Income | ¥21.63B | ¥23.59B | -8.3% |
| Profit Before Tax | ¥21.90B | ¥24.35B | -10.1% |
| Income Tax Expense | ¥6.46B | ¥7.30B | -11.6% |
| Net Income | ¥15.44B | ¥17.05B | -9.4% |
| Net Income Attributable to Owners | ¥15.42B | ¥17.02B | -9.4% |
| Total Comprehensive Income | ¥19.23B | ¥18.50B | +3.9% |
| Interest Expense | ¥68M | ¥65M | +4.6% |
| Basic EPS | ¥66.60 | ¥71.39 | -6.7% |
| Dividend Per Share | ¥21.00 | ¥21.00 | +0.0% |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥216.97B | ¥211.98B | +¥5.00B |
| Cash and Deposits | ¥91.73B | ¥87.06B | +¥4.67B |
| Accounts Receivable | ¥49.84B | ¥59.24B | ¥-9.40B |
| Inventories | ¥32.18B | ¥28.42B | +¥3.76B |
| Non-current Assets | ¥160.62B | ¥145.22B | +¥15.40B |
| Item | Value |
|---|---|
| Net Profit Margin | 14.1% |
| Gross Profit Margin | 37.5% |
| Current Ratio | 298.0% |
| Quick Ratio | 253.8% |
| Debt-to-Equity Ratio | 0.33x |
| Interest Coverage Ratio | 303.65x |
| Effective Tax Rate | 29.5% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | -1.2% |
| Operating Income YoY Change | -11.5% |
| Ordinary Income YoY Change | -8.3% |
| Net Income Attributable to Owners YoY Change | -9.4% |
| Total Comprehensive Income YoY Change | +3.9% |
| Item | Value |
|---|---|
| Shares Outstanding (incl. Treasury) | 236.52M shares |
| Treasury Stock | 6.69M shares |
| Average Shares Outstanding | 231.53M shares |
| Book Value Per Share | ¥1,231.99 |
| Item | Amount |
|---|---|
| Q2 Dividend | ¥21.00 |
| Year-End Dividend | ¥24.00 |
| Segment | Revenue | Operating Income |
|---|---|---|
| ExplosiveAndPropulsion | ¥14.73B | ¥1.29B |
| FunctionalChemicals | ¥71.53B | ¥12.35B |
| PharmaceuticalsMedicalsAndHealth | ¥25.48B | ¥8.36B |
| Item | Forecast |
|---|---|
| Net Sales Forecast | ¥258.40B |
| Operating Income Forecast | ¥46.00B |
| Ordinary Income Forecast | ¥48.30B |
| Net Income Attributable to Owners Forecast | ¥38.20B |
| Basic EPS Forecast | ¥166.18 |
| Dividend Per Share Forecast | ¥26.00 |
| Property, Plant & Equipment | ¥93.51B | ¥85.07B | +¥8.45B |
| Intangible Assets | ¥1.80B | ¥1.95B | ¥-145M |
| Investment Securities | ¥49.26B | ¥41.86B | +¥7.40B |
| Total Assets | ¥377.59B | ¥357.20B | +¥20.39B |
| Current Liabilities | ¥72.82B | ¥58.33B | +¥14.50B |
| Accounts Payable | ¥21.44B | ¥22.30B | ¥-869M |
| Short-term Loans | ¥1.49B | ¥1.49B | +¥4M |
| Non-current Liabilities | ¥21.62B | ¥19.32B | +¥2.30B |
| Long-term Loans | ¥2.49B | ¥2.01B | +¥486M |
| Total Liabilities | ¥94.44B | ¥77.65B | +¥16.79B |
| Total Equity | ¥283.15B | ¥279.55B | +¥3.60B |
| Capital Stock | ¥17.74B | ¥17.74B | ¥0 |
| Capital Surplus | ¥15.06B | ¥15.06B | ¥0 |
| Retained Earnings | ¥230.01B | ¥220.19B | +¥9.81B |
| Treasury Stock | ¥-16.27B | ¥-6.27B | ¥-10.00B |
| Owners' Equity | ¥282.15B | ¥278.53B | +¥3.62B |
| Working Capital | ¥144.15B | - | - |